Inflammatory Bowel Disease (IBD) Expanded Profile

Casandra

Casandra Test Code LC18540Version 1 (DRAFT)

Performing Lab

Lab LabcorpLab Test ID 162045CPT Codes 83516, 86036, 86671

Inflammatory Bowel Disease (IBD) Expanded Profile

Also known as: Atypical pANCA, Glycominds, IBDX

Clinical Use

Order Test

Use

Aids in the diagnosis of inflammatory bowel disease (IBD) and the differential diagnosis of Crohn's disease (CD) and ulcerative colitis (UC); prognostic aid for clinical management of patients with CD.

Special Instructions

The profile includes three novel markers: antichitobioside IgA (ACCA), antilaminaribioside IgG (ALCA), antimannobioside IgG (AMCA), alongside anti-Saccharomyces cerevisiae IgG (gASCA) and atypical perinuclear antineutrophil cytoplasmic antibody (pANCA). These markers provide additional diagnostic and prognostic information based on the combination of results.

Limitations

Results of this panel should be used in conjunction with clinical findings and other laboratory tests. There are cases where patients with inflammatory bowel disease may be negative for both ASCA and pANCA. The addition of novel serological markers improves the sensitivity of the conventional ASCA/pANCA combination, though a definitive diagnosis often requires endoscopy with biopsies for histologic examination.

Test Details

Methodology

Immunoassay (EIA)

Biomarkers

5 targets

Anti-Saccharomyces cerevisiae antibodies (gASCA)Antichitobioside carbohydrate antibodies (ACCA)Antilaminaribioside carbohydrate antibodies (ALCA)Antimannobioside carbohydrate antibodies (AMCA)Atypical perinuclear antineutrophil cytoplasmic antibody (pANCA)